EP Patent

EP1005865A1 — A anti-allergy anti-inflammatory composition comprising nimesulide and cetirizine

Assigned to Panacea Biotec Ltd · Expires 2000-06-07 · 26y expired

What this patent protects

A novel composition of Nimesulide and salts thereof and Cetrizine possessing antileukotriene, antihistaminic, antiallergic and antiinflammatory action is disclosed. The composition is useful in the cure of allergic disorders such as rhinitis, bronchitis, asthama, urticaria and th…

USPTO Abstract

A novel composition of Nimesulide and salts thereof and Cetrizine possessing antileukotriene, antihistaminic, antiallergic and antiinflammatory action is disclosed. The composition is useful in the cure of allergic disorders such as rhinitis, bronchitis, asthama, urticaria and the like.

Drugs covered by this patent

Patent Metadata

Patent number
EP1005865A1
Jurisdiction
EP
Classification
Expires
2000-06-07
Drug substance claim
No
Drug product claim
No
Assignee
Panacea Biotec Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.